Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, ...

Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is ...

Mounjaro (Tirzepatide), a groundbreaking GLP-1 receptor agonist targeting GIP receptors, is now available in India for ...

Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and ...

Zerodha CEO Nithin Kamath highlighted the transformative potential of weight-loss drugs Ozempic and Mounjaro, which help in ...

Impact of Trump’s tariffs on IT companies’ demand outlook, why kirana share in FMCG declining decoded, inward remittance data ...

I've been following the developments around Ozempic and GLP-1 drugs with some interest for a while, and last week Eli Lilly launched its variant, Mounjaro, in India. Remember, India has the highest ...

During the science exhibition at a school in Karnataka's Chamarajanagar, a teenage girl student showcased a doll wearing burqa and labelling it 'Jannati'. The video has gone viral on social media and ...

A team at Fortis Memorial Research Institute, Gurugram, removed a 10.3 kg gastrointestinal stromal tumor (GIST) from a ...

Jefferies isn’t sweating Eli Lilly’s slightly slimmer projections for its weight-loss drug Orfo, maintaining a spicy $1,020 ...